Literature DB >> 2001460

The Senegal DNA haplotype is associated with the amelioration of anemia in African-American sickle cell anemia patients.

R L Nagel1, S Erlingsson, M E Fabry, H Croizat, S M Susuka, H Lachman, M Sutton, C Driscoll, E Bouhassira, H H Billett.   

Abstract

We have previously determined that in African sickle cell anemia (SS) patients three different beta-like globin gene cluster haplotypes are associated with different percent G gamma (one of the two types of non-alpha chains comprising hemoglobin F [HbF]), mean percent HbF, and percent dense cells. We report now that in adult New York SS patients, the presence of at least one chromosome with the Senegal haplotype is associated with higher Hb levels (1.2 g/dL higher) than is found for any other non-Senegal haplotype (P less than .004). The percent reticulocytes and the serum bilirubin levels were lower in these patients. When the effect of alpha-gene number was analyzed by examining a sample of SS patients with concomitant alpha-thalassemia, the same results were obtained. Because the HbF level is significantly higher among the Senegal haplotype carriers in this sample, the inhibitory effect on sickling of this Hb variant may be one of the reasons for the haplotype effect. We conclude that the Senegal beta-like globin gene cluster haplotype is associated with an amelioration of the hemolytic anemia that characterizes sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2001460

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Minireview: Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to precision medicine.

Authors:  Steven R Goodman; Betty S Pace; Kirk C Hansen; Angelo D'alessandro; Yang Xia; Ovidiu Daescu; Stephen J Glatt
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27

2.  Whole-genome molecular haplotyping of single cells.

Authors:  H Christina Fan; Jianbin Wang; Anastasia Potanina; Stephen R Quake
Journal:  Nat Biotechnol       Date:  2010-12-19       Impact factor: 54.908

Review 3.  Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.

Authors:  Nancy S Green; Sandra Barral
Journal:  Pediatr Blood Cancer       Date:  2010-09-09       Impact factor: 3.167

4.  Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.

Authors:  Steffen E Meiler; Marlene Wade; Ferdane Kutlar; Shobha D Yerigenahally; Yongjun Xue; Laure A Moutouh-de Parseval; Laura G Corral; Paul S Swerdlow; Abdullah Kutlar
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

5.  Effects of Senegal haplotype (Xmn1-rs7412844), alpha-thalassemia (3.7kb HBA1/HBA2 deletion), NPRL3-rs11248850 and BCL11A-rs4671393 variants on sickle cell nephropathy.

Authors:  El Hadji Malick Ndour; Khuthala Mnika; Fatou Guèye Tall; Moussa Seck; Indou Dème Ly; Victoria Nembaware; Hélène Ange Thérèse Sagna-Bassène; Rokhaya Dione; Aliou Abdoulaye Ndongo; Jean Pascal Demba Diop; Nènè Oumou Kesso Barry; Moustapha Djité; Rokhaya Ndiaye Diallo; Papa Madièye Guèye; Saliou Diop; Ibrahima Diagne; Aynina Cissé; Ambroise Wonkam; Philomène Lopez Sall
Journal:  Int J Biochem Mol Biol       Date:  2022-04-15

6.  Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia.

Authors:  Danilo Grunig Humberto Silva; Edis Belini Junior; Gisele Cristine de Souza Carrocini; Lidiane de Souza Torres; Octávio Ricci Júnior; Clarisse Lopes de Castro Lobo; Claudia Regina Bonini-Domingos; Eduardo Alves de Almeida
Journal:  BMC Med Genet       Date:  2013-10-09       Impact factor: 2.103

7.  Original Research: A case-control genome-wide association study identifies genetic modifiers of fetal hemoglobin in sickle cell disease.

Authors:  Li Liu; Alexander Pertsemlidis; Liang-Hao Ding; Michael D Story; Martin H Steinberg; Paola Sebastiani; Carolyn Hoppe; Samir K Ballas; Betty S Pace
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27

Review 8.  Emerging science of hydroxyurea therapy for pediatric sickle cell disease.

Authors:  Nancy S Green; Sandra Barral
Journal:  Pediatr Res       Date:  2013-11-19       Impact factor: 3.756

Review 9.  Sickle cell anaemia: progress in pathogenesis and treatment.

Authors:  Samir K Ballas
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Comment on "Molecular analysis and association with clinical and laboratory manifestations in children with sickle cell anemia".

Authors:  Marilda Souza Goncalves
Journal:  Rev Bras Hematol Hemoter       Date:  2014-07-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.